Join Growin Stock Community!

Sanuwave health, inc.SNWV.US Overview

US StockHealthcare
(No presentation for SNWV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNWV AI Insights

SNWV Overall Performance

SNWV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNWV Recent Performance

-2.00%

Sanuwave health, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

SNWV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNWV Key Information

SNWV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNWV Profile

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Price of SNWV

SNWV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNWV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.82
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
78.26%
Net Margin
-17.06%
Revenue Growth (YoY)
40.89%
Profit Growth (YoY)
51.37%
3-Year Revenue Growth
40.08%
3-Year Profit Growth
35.85%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.82
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
78.26%
Net Margin
-17.06%
Revenue Growth (YoY)
40.89%
Profit Growth (YoY)
51.37%
3-Year Revenue Growth
40.08%
3-Year Profit Growth
35.85%
  • When is SNWV's latest earnings report released?

    The most recent financial report for Sanuwave health, inc. (SNWV) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNWV's short-term business performance and financial health. For the latest updates on SNWV's earnings releases, visit this page regularly.

  • What is the operating profit of SNWV?

    According to the latest financial report, Sanuwave health, inc. (SNWV) reported an Operating Profit of 1.47M with an Operating Margin of 12.81% this period, representing a decline of 24.88% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SNWV's revenue growth?

    In the latest financial report, Sanuwave health, inc. (SNWV) announced revenue of 11.45M, with a Year-Over-Year growth rate of 22.34%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SNWV have?

    As of the end of the reporting period, Sanuwave health, inc. (SNWV) had total debt of 24.45M, with a debt ratio of 0.69. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNWV have?

    At the end of the period, Sanuwave health, inc. (SNWV) held Total Cash and Cash Equivalents of 9.6M, accounting for 0.27 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SNWV go with three margins increasing?

    In the latest report, Sanuwave health, inc. (SNWV) achieved the “three margins increasing” benchmark, with a gross margin of 77.9%%, operating margin of 12.81%%, and net margin of 90.2%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SNWV's profit trajectory and future growth potential.

  • Is SNWV's EPS continuing to grow?

    According to the past four quarterly reports, Sanuwave health, inc. (SNWV)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SNWV?

    Sanuwave health, inc. (SNWV)'s Free Cash Flow (FCF) for the period is 556K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 54.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SNWV?

    The latest valuation data shows Sanuwave health, inc. (SNWV) has a Price-To-Earnings (PE) ratio of -32.16 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.